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Summary Intact SWAII antibody was evaluated as a potential radioimmunotherapeutic agent against small
cell lung cancer xenografts in a nude mouse model system. I3II-labelled SWAII was given either in a single
injection regimen (I x 300#tCi) or as a multiple injection regimen achieving a total of 900pCi (3 x 300 pCi
with a 2 week interval between injections). Treatment of both small (mean volume approximately 0.2 cm3) and
large (mean volume approximately 1.0 cm3) established xenografts resulted in significant anti-tumour effects
and, in the case of the fractionated protocol, the failure of the xenografts to regrow within the period of
observation (84 days). Xenograft histology following radioimmunotherapy showed large areas of necrosis,
fibrosis and very few residual cells of SCLC origin.
Small cell cancer of the lung (SCLC) is a highly chemo- and
radiosensitive disease for which the long term prognosis re-
mains poor. Following initial chemotherapy, a fatal relapse
caused by a re-emergent chemoresistant form of the disease
occurs in most patients (De Leij et al., 1987). Between first
treatment and relapse, the disease exists as widely spread
small cellular foci which may retain their radiosensitivity. In
an effort to develop new anti-SCLC diagnostic and thera-
peutic agents we have generated a panel of murine mono-
clonal antibodies directed against target SW2 cells of SCLC
origin. We describe here a therapeutic study with the IgG2a
antibody SWAl (Smith et al., 1989) in a nude mouse model
system. The successful application of radioimmunotherapy
(RIT) for the treatment of malignant conditions depends
upon many contributing factors of which the actual disease
chosen for therapy is among the most important. Malignant
disease such as SCLC, which may occur dispersed through-
out the body as relatively small and radiosensitive foci, fulfils
the conditions of a suitable target tumour as described by
Dykes et al. (1987). The requirement for new treatment
modalities is underlined by the high mortality of the disease
when treated with current therapeutic protocols (de Vita et
al., 1985; Carney, 1987).
Materials and methods
Cell line
The SCLC cell line SW2 was established in the laboratory of
Dr S.D. Bernal, Dana Farber Institute. It was routinely
grown in RPMI medium supplemented with 1 mM glutamine
and 10% foetal calf serum.
Monoclonal antibody
Our procedure for antibody generation has been previously
described (Stahel et al., 1985). The IgG2a antibody SWAl
was purified as follows. A 30-55% ammonium sulphate
fraction was taken from culture supernatant and adsorbed
onto a protein A column in binding buffer. The adsorbed
IgG was eluted with 100 mM citrate buffer (pH 4.5) and then
dialysed against 10 mM phosphate buffer (pH 6.8) containing
0.01 mM CaCl2. The antibody was then applied to a hydrox-
ylapatite column (Bio-Gel HPHT, Bio-Rad, Richmond, CA)
and eluted with a linear gradient to 350 mM phosphate. As
an appropriate control antibody an anti-CEA murine mono-
clonal of the same isotype was used.
Antibody labelling technique
0.1 mg Iodogen (Pierce) was dissolved in 0.2 ml chloroform
and added to a 1 ml vial. The solvent was evaporated with a
gentle stream of nitrogen and then 0.5 mg of SWA 11
antibody in 0.5 M phosphate buffer added. The required
amount of '"'I was added and the reaction continued for
15 min at 10°C with stirring. The reaction mixture was
applied to a prepacked Sephadex G50 column which had
been equilibrated with PBS (0.05 M phosphate buffer, 0.1 M
sodium chloride, pH 7.4). The solution was sterilised by pas-
sage through a 0.22 micron filter (Millex GV). Bovine serum
albumin (1%) was added as protein carrier and the percen-
tage of counts bound to protein estimated by trichloracetic
acid precipitation (20% solution), performed for 2 h at 4°C.
Radiochemical purity was generally in excess of 95%. (Where
multiple injections of radioimmunoconjugate were to be
given no bovine serum albumin was added to the radio-
labelled preparation so as to avoid the risk of anaphylactic
shock.)
Resistance to radiolabelling
To establish that no impairment of the biological activity of
SWAl antibody would be caused by I3lI-labelling in the
anticipated range the antibody was labelled to specific
activities between 2.5 and 25 mCi mg-'. Labelled SWAl at
a concentration which had been determined to give half
maximal binding was then evaluated in a fixed cell radio-
immunoassay. The number of counts bound to target SW2
cells were then plotted against the specific activity of the
radiolabelled SWAl preparation.
In vitro immunoreactivity
To determine accurately the biological activity of radio-
labelled SWA 11 intended for use in RIT studies, SW2 cells
were washed x 3 in PBS (with 5% non-fat milk, 0.05%
azide) and varying cell numbers (from 0.625 x 106 to 107)
were then incubated for 2 h at 4°C with a fixed amount of
radiolabelled antibody. After washing as above the activity in
the cell pellet was counted. The number of counts remaining
unbound were plotted against the reciprocal of the cell
number so that the intercept on the y axis indicates the
theoretical unreactive fraction. The difference between the
input and the estimated unreactive fraction (both in c.p.m.)
represents the biological activity of the radiolabelled anti-
body (Trucco & de Petris, 1981).
The SW2 xenograft model
Female NMRI nu/nu mice were bred within the Biologisches
Zentrallabor, Universitaetsspital, Zurich. The animals were
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maintained on pathogen free food and acidified drinking
water which were given ad libitum. Xenograft passage was
performed by subcutaneous transplantation of 2-3 mm3
pieces of SW2 tumour into 4-6 week old animals under
ether anaesthesia.
Radioimmunotherapy studies
In order to minimise the number of animals used in this
study the assumption was made that if control materials
failed to inhibit the growth of small (around 0.2 cm3) SCLC
xenografts then they would also be unable to inhibit the
growth of larger more well established xenografts (Sharkey et
al., 1987). In consequence diluent, unlabelled SWAl1 anti-
body and 300IACi '3ll-anti-CEA antibody were administered
to mice bearing small SCLC xenografts in equivalent
amounts to those used in the single dose therapeutic studies.
In the single dose therapy protocol, groups of nude mice
bearing established xenografts of mean volume approxi-
mately either 0.2 or 1.0 cm3 were injected i.v. with 100fig
SWA 11 labelled with 300fiCi "''I. For multiple dose therapy
the animals were injected x 3 with 300jsCi of 131I-SWA11
with a 2 week interval between injections. Tumour growth
rates were then assessed using the formula of Kopper and
Steel (1975). Animal weight loss was also monitored during
the experiment and was found to be transient and in no
instance more than 20% of initial body weight.
Xenograft histology
At day 84 all animals treated with 3 x 300 gsCi '3'SWA1 1
were killed and residual tumours fixed in 4% formalin solu-
tion. Sections were stained with haematoxylin and eosin and
then compared with tumour sections taken from diluent
treated control animals.
Results
Resistance to radiolabelling
Figure 1 shows the binding of 1311 SWAl1, labelled over the
range of specific activities 2.5-25 mCi mg-', to SW2 cells in
a fixed cell radioimmunoassay. Increased specific activity is
seen to result in accompanying increase in counts bound to
target cells up to an activity of 15 mCi mg-' thereby indicat-
ing SWA 11 to retain its biological activity over the indicated
range of labelling. Little increase in c.p.m. bound was observ-
ed between 15 and 25 mCi mg-' suggesting impairment of
immunoreactivity.
In vitro immunoreactivity
The iodogen radiolabelling reagent was routinely employed
to produce iodinated SWA 1. The biological activity of the
labelled antibody intended for use in RIT studies was nor-
mally around 65-70% as shown in Figure 2.
Radioimmunotherapy studies
The administration of unlabelled SWAl1 or 300fiCi "' I-
labelled anti-CEA control antibody had no significant effect
on the growth rate of small (around 0.2 cm3) SCLC xeno-
grafts when compared to the diluent control group (Figure
3a).
In the single injection study the mean starting volumes of
the small and large tumour groups were 0.18 (± 0.08) and
0.95 (± 0.13) cm3 respectively. In the case of small tumours
the injection of 300jiCi 13'1-labelled SWA 11 resulted in
marked tumour shrinkage and no evidence of regrowth until
after day 34 post-injection. Rapid growth then resumed up to
day 70 when the animals were killed. Large tumours were
less susceptible to treatment showing no change in volume up
to day 14 followed by resumed rapid growth (see Figure 3b).
At the start of the multiple dose protocol mean tumour
volumes were 0.15 (± 0.07) cm3 and 1.3 (± 0.10) cm3 for the
small and large tumour groups respectively. The small
tumour group shrank to a minimum volume by day 49 and
remained static until termination of the experiment at day 84.
The large tumour group shows a fall in mean tumour
volume to a minimum at day 56 (i.e. 28 days after the last
injection). As in the small tumour group, no evidence of
regrowth was observed up to termination of the experiment
(Figure 4).
SCLC xenograft histology
Typical histological sections of diluent and fractionated '1'I-
SWAI1 treated tumours are shown in Figure 5. Diluent
treated tumours (Figure Sa) showed typical SCLC histology
possessing densely packed small cells with intense nuclear
staining. Both large and small tumour xenografts treated
with 3 x 300jsCi 131I-SWA1 1 showed similar radical changes
in histology. Figure Sb shows typical histology after frac-
tionated therapy of a large tumour xenograft in which the
tumour tissue is extensively replaced by dense connective
tissue and large areas of necrosis are evident. A few cells of
SCLC origin are still observed, although their appearance is
atypical being somewhat enlarged and lacking mitotic figures.
Reciprocal of (cell number x 10-8)
Figure 1 Resistance of SWAlI to radiolabelling procedures.
SWA 1I was labelled with 13' I over a range of specific activities
from 2.5-25mCimg-' and was then used in a radioimmuno-
assay against fixed SW2 cells at a concentration determined to
give half maximal binding. Resultant c.p.m. bound (with s.d.) to
target SW2 cells are plotted against specific activity.
Figure 2 Assessment of the biological activity of radiolabelled
SWAI1. Antibody was incubated with increasing concentrations
of SW2 cells as described in the text. The number of counts
remaining unbound were then plotted against the reciprocal of
the cell number. Knowing the input in c.p.m. the biologically
active fraction is determined by extrapolation to the ordinate.
mCi mg-'
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Figure 3 a and b. The effect of diluent alone (0 0), unlabelled SWAl1 (0 0) or 300 LCi 131I-labelled control antibody
(0-0) on the growth of small established SCLC xenografts a, and the effect of 300fiCi '31I-SWA 1 on the growth of both small
and large SCLC xenografts b. Bars indicate s.d. obtained using groups of three animals.
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Figure 4 Fractionated radioimmunotherapy of small and large
SCLC xenografts. Animals were injected with 300iLCi 31I-
SWA 11 an days 0, 14 and 28. The experiment was terminated at
day 84. Bars indicate s.d. obtained using groups of three animals.
b
Discussion
Reports in the literature of successful radioimmunotherapy
of human tumour xenografts are few and restricted to the
treatment of xenografts derived from highly radiosensitive
tumour types such as neuroblastoma (Cheung et al., 1986) or
to model systems in which fractionated protocols have been
adopted (Buchegger et al., 1990; Schlom et al., 1990).
Radioimmunotherapy of SCLC xenografts was originally
described by Yoneda et al. (1988). A single injection of
500 tCi "1'I-labelled TSF-4 antibody resulted in shrinkage of
well established SCLC xenografts to 60% of their original
volume (0.5-1.0 cm3). The administration of 2 x 500 JLCi
with 5 weeks interval gave a more prolonged retardation of
tumour growth so that xenografts were only just over 200%
of their starting volume at day 79 post first injection. In the
study presented here a lower single dose of only 300pCi
resulted in xenograft volume reductions of 58 and 9% for
small and large tumour groups respectively. These results
seem to be roughly comparable with those of Yoneda if
allowance is made for experimental variations of injected
dose and tumour volume, although the effect of difference in
radiosensitivity of the target xenografts can not bc evaluated
without further experimentation.
More interesting, however, is the consequence of multiple
treatment. The study of Yoneda employed two injections of
500 jlCi with an interval of 5 weeks. This strategy resulted in
I
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Figure 5 a and b. Histology of tumour xenografts treated with
either diluent a, or 3 x 300 jiCi I3II-SWAl b. Tumours were
removed at days 16 and 84 respectively and formalin fixed.
Sections were stained using haematoxylin and eosin. C = connec-
tive tissue and SCLC = residual cells of small cell origin.
a similar marked reduction in tumour volume following each
treatment, but the interval between injections was so long
that prior to the second injection regrowth occurred to a
volume almost 1.5 times greater than the starting volume.
The present study used a lower total dose of 900 .Ci admin-
istered at three injections of 300ltCi with an interval of only
2 weeks between treatments. With this protocol tumour
volume was progressively reduced and showed no evidence of
a
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regrowth to day 84 of the study. This strategy of giving
second and third treatments before an opportunity for
tumour regrowth has occurred seems to have strongly
enhanced the overall antitumour effect of the '31I-SWA1 1
conjugate as compared to the '3'I-TSF-4 conjugate of
Yoneda.
The apparent ablation of well established SCLC xenografts
by fractionated radioimmunotherapy is an encouraging result
although conclusions as to the efficacy of radiolabelled anti-
bodies in the clinical situation can not be made directly from
data obtained in a mouse model system. However, the work
presented here confirms the status of SCLC as a prime target
for tumour-specific radioimmunotherapy due to its high
radiosensitivity and augures well for the eventual application
of radioimmunotherapy as part of a combined modality
approach to the treatment of SCLC.
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